News

Tuesday, 19. March 2019 | Filed under Company News

Company News: ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

Recognition for outstanding and innovative cancer research

ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute. Read more…

Monday, 18. February 2019 | Filed under Company News

Company News: Curetis’ Subsidiary Ares Genetics and QIAGEN Enter into Bioinformatics Partnership to Fight Antimicrobial Resistance

— QIAGEN becomes exclusive partner for bioinformatics research applications based on ARESdb and AREStools

— Partnership intends to create a community platform for antimicrobial resistance research

Curetis N.V. (the “Company” and together with its subsidiaries “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (Vienna, Austria) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) have entered into a strategic licensing agreement for ARESdb and AREStools in the area of antimicrobial resistance (AMR) research. Read more…

Monday, 18. February 2019 | Filed under Innovation Radar

Innovation Radar: Understanding science / Testing CRISPR-Cas9 in the lab

Last weekend, akampion went back to the lab for a day to get a first-hand experience of genome editing.  In an event organized by Science Bridge e.V. and supported by DFG, Joachim Herz Stiftung and Kassel University, selected participants were able to perform genome editing on an E. coli strain. Read more…